$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2012 Form 10-K Financial Statement

#000119312513085450 Filed on March 01, 2013

Income Statement

Concept	2012	2011 Q4	2011 Q3
Revenue	$8.186B	$1.662B	$1.758B
YoY Change	21.61%	0.91%	6.56%
Cost Of Revenue	$5.584B	$1.167B	$1.190B
YoY Change	20.5%	2.98%	3.94%
Gross Profit	$2.603B	$495.2M	$568.2M
YoY Change	24.07%	-3.64%	12.49%
Gross Profit Margin	31.8%	29.8%	32.32%
Selling, General & Admin	$894.0M	$96.80M	$184.5M
YoY Change	29.94%	-51.79%	-3.81%
% of Gross Profit	34.34%	19.55%	32.47%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$299.8M	$73.00M	$67.80M
YoY Change	20.91%	21.46%	15.9%
% of Gross Profit	11.52%	14.74%	11.93%
Operating Expenses	$1.235B	$167.3M	$252.1M
YoY Change	29.73%	-35.8%	0.8%
Operating Profit	$1.297B	$329.7M	$318.4M
YoY Change	12.33%	29.18%	24.01%
Interest Expense	-$284.0M	-$59.60M	-$58.20M
YoY Change	22.41%	14.84%	54.38%
% of Operating Profit	-21.9%	-18.08%	-18.28%
Other Income/Expense, Net	$3.737M	$800.0K	$800.0K
YoY Change	25.32%	-27.27%	0.0%
Pretax Income	$1.001B	$268.8M	$258.3M
YoY Change	9.24%	103.28%	18.5%
Income Tax	$359.8M	$101.3M	$94.20M
% Of Pretax Income	35.94%	37.69%	36.46%
Net Earnings	$536.0M	$148.1M	$135.4M
YoY Change	12.14%	114.61%	13.38%
Net Earnings / Revenue	6.55%	8.91%	7.7%
Basic Earnings Per Share	$2.79	$1.59	$1.45
Diluted Earnings Per Share	$2.74	$1.56	$1.42
COMMON SHARES
Basic Shares Outstanding	192.0M		93.44M shares
Diluted Shares Outstanding	195.9M		95.17M shares

Balance Sheet

Concept	2012	2011 Q4	2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$541.0M	$411.0M	$566.0M
YoY Change	31.63%	-53.45%	1.43%
Cash & Equivalents	$534.0M	$393.8M	$541.2M
Short-Term Investments	$7.000M	$17.00M	$25.00M
Other Short-Term Assets	$517.0M	$49.35M	$324.0M
YoY Change	57.14%	12.17%	25.1%
Inventory	$78.00M	$75.73M	$73.00M
Prepaid Expenses		$48.26M
Receivables	$1.424B	$1.195B	$1.165B
Other Receivables	$321.0M	$282.0M	$242.0M
Total Short-Term Assets	$2.882B	$2.293B	$2.370B
YoY Change	25.69%	-12.57%	4.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.872B	$1.433B	$1.336B
YoY Change	30.64%	22.36%	19.07%
Goodwill		$4.947B
YoY Change		20.91%
Intangibles		$159.5M
YoY Change		-1.93%
Long-Term Investments	$94.00M	$37.00M	$39.00M
YoY Change	154.05%	5.71%	14.71%
Other Assets	$80.00M	$34.23M	$32.00M
YoY Change	135.29%	6.79%	0.0%
Total Long-Term Assets	$13.12B	$6.611B	$6.337B
YoY Change	98.49%	20.38%	18.12%
TOTAL ASSETS
Total Short-Term Assets	$2.882B	$2.293B	$2.370B
Total Long-Term Assets	$13.12B	$6.611B	$6.337B
Total Assets	$16.00B	$8.904B	$8.707B
YoY Change	79.74%	9.73%	14.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$414.0M	$289.7M	$259.0M
YoY Change	42.76%	60.0%	-19.31%
Accrued Expenses	$567.0M	$616.0M	$462.0M
YoY Change	-24.4%	89.54%	29.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$228.0M	$87.35M	$82.00M
YoY Change	162.07%	16.63%	-14.58%
Total Short-Term Liabilities	$2.011B	$1.165B	$1.206B
YoY Change	72.62%	26.01%	8.45%
LONG-TERM LIABILITIES
Long-Term Debt	$8.327B	$4.418B	$4.417B
YoY Change	88.48%	4.34%	35.24%
Other Long-Term Liabilities	$458.0M	$132.0M	$156.0M
YoY Change	201.32%	47.84%	33.33%
Total Long-Term Liabilities	$8.785B	$4.550B	$4.573B
YoY Change	92.23%	5.24%	35.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.011B	$1.165B	$1.206B
Total Long-Term Liabilities	$8.785B	$4.550B	$4.573B
Total Liabilities	$12.24B	$6.157B	$6.707B
YoY Change	81.0%	8.14%	26.4%
SHAREHOLDERS EQUITY
Retained Earnings		$3.196B
YoY Change		17.59%
Common Stock		$135.0K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$1.632B
YoY Change		19.93%
Treasury Stock Shares		41.22M shares
Shareholders Equity	$3.763B	$2.141B	$1.999B
YoY Change
Total Liabilities & Shareholders Equity	$16.00B	$8.904B	$8.707B
YoY Change	79.74%	9.73%	14.16%

Cashflow Statement

Concept	2012	2011 Q4	2011 Q3
OPERATING ACTIVITIES
Net Income	$536.0M	$148.1M	$135.4M
YoY Change	12.14%	114.61%	13.38%
Depreciation, Depletion And Amortization	$299.8M	$73.00M	$67.80M
YoY Change	20.91%	21.46%	15.9%
Cash From Operating Activities	$1.101B	$150.6M	$495.2M
YoY Change	-6.71%	24.88%	207.01%
INVESTING ACTIVITIES
Capital Expenditures	$550.1M	-$148.3M	-$97.00M
YoY Change	37.48%	42.32%	38.57%
Acquisitions
YoY Change
Other Investing Activities	-$4.282B	-$118.0M	-$727.5M
YoY Change	328.62%	150.53%	1502.42%
Cash From Investing Activities	-$4.832B	-$266.2M	-$824.4M
YoY Change	245.37%	75.94%	613.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$39.29B
YoY Change	8.38%
Cash From Financing Activities	3.872B	-31.90M	140.6M
YoY Change	-1666.61%	-108.95%	-263.49%
NET CHANGE
Cash From Operating Activities	1.101B	150.6M	495.2M
Cash From Investing Activities	-4.832B	-266.2M	-824.4M
Cash From Financing Activities	3.872B	-31.90M	140.6M
Net Change In Cash	140.8M	-147.5M	-188.6M
YoY Change	-130.19%	-145.3%	369.15%
FREE CASH FLOW
Cash From Operating Activities	$1.101B	$150.6M	$495.2M
Capital Expenditures	$550.1M	-$148.3M	-$97.00M
Free Cash Flow	$550.7M	$298.9M	$592.2M
YoY Change	-29.39%	32.96%	156.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	dva	Line Of Credit Facility Additional Borrowing Capacity LineOfCreditFacilityAdditionalBorrowingCapacity	3000000000
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	105500000	shares
CY2013Q1	dei	Entity Public Float EntityPublicFloat	12200000000
CY2012Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	94500000	shares
CY2012Q2	dei	Entity Public Float EntityPublicFloat	9300000000
CY2010Q4	dva	Stock Repurchase Program Additional Authorized Repurchase Amount StockRepurchaseProgramAdditionalAuthorizedRepurchaseAmount	800000000
CY2011Q3	dva	Number Of Centers Sold NumberOfCentersSold	28	Entity
CY2011Q4	dva	Number Of Centers Sold NumberOfCentersSold	2	Entity
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	539459000
CY2010Q4	us-gaap	Goodwill Goodwill	4091307000
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8138000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	860117000
CY2010Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	503000
CY2011Q4	us-gaap	Goodwill Goodwill	4946976000
CY2011Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	34173000
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2737143000
CY2011Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	463927000
CY2011Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	4512811000
CY2011Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	280382000
CY2011Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	328607000
CY2011Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	72835000
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	49349000
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14728000
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-142716000
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34231000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	2141075000
CY2011Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	8081000
CY2011Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1269343000
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	144124000
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29163000
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Gain Loss AvailableForSaleSecuritiesGrossUnrealizedGainLoss	-255000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	163770000
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2268125000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2011Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	37412000
CY2011Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Noncontrolling Interest TemporaryEquityCarryingAmountAttributableToNoncontrollingInterest	478216000
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	421735000
CY2011Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	7842000
CY2011Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	41220920	shares
CY2011Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	606643000
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	87345000
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93641363	shares
CY2011Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	335012000
CY2011Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	15174000
CY2011Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	4417624000
CY2011Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	193966000
CY2011Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	439203000
CY2011Q4	us-gaap	Liabilities Liabilities	6157467000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	289653000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8943000
CY2011Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	48256000
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	117831000
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	64120000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	132006000
CY2011Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	164404000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1164752000
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	250343000
CY2011Q4	us-gaap	Senior Notes SeniorNotes	1550000000
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Long Term Investments LongTermInvestments	9890000
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3195818000
CY2011Q4	us-gaap	Assets Assets	8903808000
CY2011Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	9890000
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	423098000
CY2011Q4	us-gaap	Investments Investments	27289000
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1195163000
CY2011Q4	us-gaap	Inventory Net InventoryNet	75731000
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8903808000
CY2011Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1266499000
CY2011Q4	us-gaap	Long Term Debt LongTermDebt	4504969000
CY2011Q4	us-gaap	Minority Interest MinorityInterest	127050000
CY2011Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	41514000
CY2011Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1631694000
CY2011Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	66011000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393752000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	409104000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	134862283	shares
CY2011Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	43364000
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	159491000
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-19484000
CY2011Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	71446000
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	17399000
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	135000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Interest Payable Current InterestPayableCurrent	17469000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	249613000
CY2011Q4	us-gaap	Land Land	23004000
CY2011Q4	us-gaap	Assets Current AssetsCurrent	2293244000
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	478655000
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2011Q4	us-gaap	Other Receivables OtherReceivables	281468000
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1304492000
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1432651000
CY2011Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	27325000
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	563365000
CY2012Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	78073000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	201572000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12585000
CY2011Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	596300000
CY2011Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	3036000
CY2011Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	3420000
CY2011Q4	dva	Percentage Of Accounts Receivable Six Months Or More Past Due PercentageOfAccountsReceivableSixMonthsOrMorePastDue	0.16	pure
CY2011Q4	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	11754000
CY2011Q4	dva	Alliance And Product Supply Agreement Net AllianceAndProductSupplyAgreementNet	19987000
CY2011Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	4992715000
CY2011Q4	dva	Alliance And Product Supply Agreement Gross AllianceAndProductSupplyAgreementGross	68200000
CY2011Q4	dva	Deferred Tax Assets Alliance And Product Supply Agreement DeferredTaxAssetsAllianceAndProductSupplyAgreement	7775000
CY2011Q4	dva	Amortized Intangible Liabilities Accumulated Amortization AmortizedIntangibleLiabilitiesAccumulatedAmortization	48213000
CY2011Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	37447000
CY2011Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	125159000
CY2011Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	704329000
CY2011Q4	dva	Mutual Funds And Common Stock At Fair Value MutualFundsAndCommonStockAtFairValue	15535000
CY2011Q4	dva	Other Current Assets Other OtherCurrentAssetsOther	1093000
CY2011Q4	dva	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	19987000
CY2012Q4	us-gaap	Goodwill Goodwill	8964969000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	329592000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	9593000
CY2012Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	227791000
CY2012Q4	us-gaap	Finite Lived Computer Software Gross FiniteLivedComputerSoftwareGross	184686000
CY2012Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	148881000
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3394676000
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	509832000
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8575870000
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	315782000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-390966000
CY2012Q4	us-gaap	Escrow Deposit EscrowDeposit	70922000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	80194000
CY2012Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	841648000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	3763137000
CY2012Q4	us-gaap	Other Finite Lived Intangible Assets Gross OtherFiniteLivedIntangibleAssetsGross	9574000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	260109000
CY2012Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	461102000
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1578098000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	104707000
CY2012Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	137387000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	58530000
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Gain Loss AvailableForSaleSecuritiesGrossUnrealizedGainLoss	2146000
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	102718000
CY2012Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	908013000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	229757000
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3928048000
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Noncontrolling Interest TemporaryEquityCarryingAmountAttributableToNoncontrollingInterest	580692000
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	566911000
CY2012Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	21545000
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	29363708	shares
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	900798000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	308147000
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	227791000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	105498575	shares
CY2012Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	41706000
CY2012Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	460011000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	96594000
CY2012Q4	us-gaap	Liabilities Of Assets Held For Sale LiabilitiesOfAssetsHeldForSale	18440000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	287224000
CY2012Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	17976000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	9780000
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8326534000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	306730000
CY2012Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	163520000
CY2012Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	352948000
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	698225000
CY2012Q4	us-gaap	Liabilities Liabilities	11509856000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	414143000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	67546000
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	75853000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	9635000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	103458000
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	56391000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	443743000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	232764000
CY2012Q4	us-gaap	Senior Notes SeniorNotes	2800000000
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	55454000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	141216000
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	59341000
CY2012Q4	us-gaap	Finite Lived Trade Names Gross FiniteLivedTradeNamesGross	170494000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3731835000
CY2012Q4	us-gaap	Assets Assets	16018596000
CY2012Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	13985000
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	706748000
CY2012Q4	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0473	pure
CY2012Q4	us-gaap	Investments Investments	21123000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	9525000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1421303000
CY2012Q4	us-gaap	Inventory Net InventoryNet	78126000
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16018596000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	9703000
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1494677000
CY2012Q4	us-gaap	Long Term Debt LongTermDebt	8554325000
CY2012Q4	us-gaap	Minority Interest MinorityInterest	164911000
CY2012Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	92667000
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1162336000
CY2012Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	121176000
CY2012Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	350000000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	533748000
CY2012Q4	us-gaap	Other Assets Held For Sale Current OtherAssetsHeldForSaleCurrent	51547000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2432101000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	134862283	shares
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	44622000
CY2012Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	92980000
CY2012Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	96594000
CY2012Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	5500000	shares
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2127778000
CY2012Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	263821000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	791068000
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15297000
CY2012Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	174685000
CY2012Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	195639000
CY2012Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	1486160000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2018174000
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	245122000
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	7138000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	135000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1891094000
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	44884000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	304323000
CY2012Q4	us-gaap	Land Land	35633000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	2878794000
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	522417000
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2207487000
CY2012Q4	us-gaap	Other Receivables OtherReceivables	265671000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1522306000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1872370000
CY2012Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	35150000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1208800000
CY2012Q4	us-gaap	Other Commitment OtherCommitment	3000000
CY2012Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	6934000
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	12073000
CY2012Q4	dva	Percentage Of Accounts Receivable Six Months Or More Past Due PercentageOfAccountsReceivableSixMonthsOrMorePastDue	0.17	pure
CY2012Q4	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	5938000
CY2012Q4	dva	Major Facility Lease Terms Minimum Period In Years MajorFacilityLeaseTermsMinimumPeriodInYears	5	Y
CY2012Q4	dva	Major Facility Lease Terms Maximum Period In Years MajorFacilityLeaseTermsMaximumPeriodInYears	15	Y
CY2012Q4	dva	Renewal Option Terms Minimum Additional Period In Years RenewalOptionTermsMinimumAdditionalPeriodInYears	5	Y
CY2012Q4	dva	Renewal Option Terms Maximum Additional Period In Years RenewalOptionTermsMaximumAdditionalPeriodInYears	10	Y
CY2012Q4	dva	Alliance And Product Supply Agreement Net AllianceAndProductSupplyAgreementNet	14657000
CY2012Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9491682000
CY2012Q4	dva	Alliance And Product Supply Agreement Gross AllianceAndProductSupplyAgreementGross	68200000
CY2012Q4	dva	Deferred Tax Assets Alliance And Product Supply Agreement DeferredTaxAssetsAllianceAndProductSupplyAgreement	5702000
CY2012Q4	dva	Amortized Intangible Liabilities Accumulated Amortization AmortizedIntangibleLiabilitiesAccumulatedAmortization	53543000
CY2012Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	64276000
CY2012Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	127109000
CY2012Q4	dva	Long Term Debt Maturities Repayments Of Principal In Year Six And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSixAndThereafter	4443503000
CY2012Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	923743000
CY2012Q4	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	292042000
CY2012Q4	dva	Held To Maturity Securities Released From Regulatory Agencies HeldToMaturitySecuritiesReleasedFromRegulatoryAgencies	7100000
CY2012Q4	dva	Mutual Funds And Common Stock At Fair Value MutualFundsAndCommonStockAtFairValue	15185000
CY2012Q4	dva	Share Based Compensation Shares Authorized Under Stock Option Plans Stock Appreciation And Stock Units Exercise Price Range Number Of Awards Exercisable ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansStockAppreciationAndStockUnitsExercisePriceRangeNumberOfAwardsExercisable	1911727	shares
CY2012Q4	dva	Share Based Compensation Shares Authorized Under Stock Option Plans Stock Appreciation And Stock Units Exercise Price Range Number Of Awards Outstanding ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansStockAppreciationAndStockUnitsExercisePriceRangeNumberOfAwardsOutstanding	7347848	shares
CY2012Q4	dva	Number Of Entities That Third Parties Held Non Controlling Ownership NumberOfEntitiesThatThirdPartiesHeldNonControllingOwnership	250	Entity
CY2012Q4	dva	Exercise Price Of Warrants ExercisePriceOfWarrants	14.22
CY2012Q4	dva	Percentage Of Outstanding Patient Accounts Receivables PercentageOfOutstandingPatientAccountsReceivables	1.00	pure
CY2012Q4	dva	Accounts Receivable Months Outstanding AccountsReceivableMonthsOutstanding	P4M
CY2012Q4	dva	Assets Held For Sale Goodwill AssetsHeldForSaleGoodwill	31853000
CY2012Q4	dva	Other Current Assets Other OtherCurrentAssetsOther	3250000
CY2012Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	226000
CY2012Q4	dva	Intangible Lease Liabilities IntangibleLeaseLiabilities	5338000
CY2012Q4	dva	Contingent Earnout Liability ContingentEarnoutLiability	142244000
CY2012Q4	dva	Finite Lived Intangible Liabilities Net FiniteLivedIntangibleLiabilitiesNet	19995000
CY2012Q4	dva	Medical Expense Payable MedicalExpensePayable	245964000
CY2012Q4	dva	Accrued Medical Claims Current AccruedMedicalClaimsCurrent	39698000
CY2011Q4	us-gaap	Payments To Acquire Available For Sale Securities Equity PaymentsToAcquireAvailableForSaleSecuritiesEquity	3555000
CY2012Q3	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	The 5 3/4% New Senior Notes will pay interest on February 15 and August 15 of each year, beginning February 15, 2013.
CY2011Q3	dva	Number Of Centers To Be Divest NumberOfCentersToBeDivest	30	Entity
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	1727000
CY2010	us-gaap	Costs And Expenses CostsAndExpenses	5225802000
CY2010	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	4740000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeTax	-3536000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	67935000
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	993808000
CY2010	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	17273000
CY2010	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	113810000
CY2010	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	26706000
CY2010	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	78536000
CY2010	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	9905000
CY2010	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4228000
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-392000
CY2010	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	56615000
CY2010	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-3854000
CY2010	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	24134502000
CY2010	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	403956000
CY2010	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	48686000
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	411734000
CY2010	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-643338000
CY2010	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	78536000
CY2010	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-5835000
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217793000
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	45551000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2010	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	482364000
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.94
CY2010	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	480000
CY2010	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	67901000
CY2010	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3410000
CY2010	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3566000
CY2010	us-gaap	Profit Loss ProfitLoss	484219000
CY2010	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax	-3453000
CY2010	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	5423000
CY2010	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	618496000
CY2010	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	6219610000
CY2010	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	153502000
CY2010	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1555000	shares
CY2010	us-gaap	Depreciation And Amortization DepreciationAndAmortization	231548000
CY2010	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.349	pure
CY2010	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	22727000
CY2010	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	53760000
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	839683000
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-436633000
CY2010	us-gaap	Income Taxes Paid IncomeTaxesPaid	207265000
CY2010	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	7498000
CY2010	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	355464000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	5557000
CY2010	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-134000
CY2010	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	9342000
CY2010	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	1855000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.039	pure
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	273602000
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	320658000
CY2010	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	59932000
CY2010	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	39588000
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	571825000
CY2010	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	24809258000
CY2010	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-901000
CY2010	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax	-217000
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103059171	shares
CY2010	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	-68000
CY2010	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3419000
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-55379000
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	741238000
CY2010	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	6051000
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.00
CY2010	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	6049266000
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-82392000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	-9000
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1007000
CY2010	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	14214000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	13000
CY2010	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	3.98
CY2010	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	5882965000
CY2010	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	1029000
CY2010	us-gaap	Net Income Loss NetIncomeLoss	405683000
CY2010	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	6283000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.040	pure
CY2010	us-gaap	Interest Expense Debt InterestExpenseDebt	172265000
CY2010	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	1125000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	22000
CY2010	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	2621000
CY2010	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax	8876000
CY2010	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	83591000
CY2010	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	336645000
CY2010	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	6283000
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101504373	shares
CY2010	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3892000
CY2010	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	31338000
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	266100000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2010	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	1365000
CY2010	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8999000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.001	pure
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45551000
CY2010	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	900000
CY2010	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-401000
CY2010	us-gaap	Interest Paid InterestPaid	190949000
CY2010	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	83000
CY2010	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	75399000
CY2010	us-gaap	Tax Benefit From Stock Options Exercised1 TaxBenefitFromStockOptionsExercised1	26706000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeBeforeTax	9093000
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1452000	shares
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	258874000
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	405615000
CY2010	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.92
CY2010	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	490270000
CY2010	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-111444000
CY2010	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	1855000
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	615000
CY2010	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19085000
CY2010	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	188502000
CY2010	us-gaap	Contributions From Noncontrolling Interests ContributionsFromNoncontrollingInterests	9510000
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	405615000
CY2010	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	628000
CY2010	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-45737000
CY2010	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	44719000
CY2010	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	560946000
CY2010	dva	Supplemental Assets Acquired Under Capital Leases SupplementalAssetsAcquiredUnderCapitalLeases	3983000
CY2010	dva	Patient Care Costs PatientCareCosts	4427862000
CY2010	dva	Debt Expense DebtExpense	181607000
CY2010	dva	Debt Refinancing Charge DebtRefinancingCharge	74382000
CY2010	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	3298000
CY2010	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	234378000
CY2010	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	361000
CY2010	dva	Increase Non Controlling Interest IncreaseNonControllingInterest	1139000
CY2010	dva	Income Tax Expense Benefit Continuing Operations And Discontinued Operations IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations	260239000
CY2010	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	399848000
CY2010	dva	Debt Refinancing And Redemption Charges DebtRefinancingAndRedemptionCharges	74382000
CY2010	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	44421000
CY2010	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	9585000
CY2010	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	255989000
CY2010	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	403888000
CY2010	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	403888000
CY2010	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	101497000	shares
CY2010	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	7000	shares
CY2010	dva	Payments For Proceeds To Acquire Equity Method Investments And Other Assets PaymentsForProceedsToAcquireEquityMethodInvestmentsAndOtherAssets	709000
CY2010	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-2744000
CY2010	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	166301000
CY2010	dva	Provision For Doubtful Accounts Discontinued Operations ProvisionForDoubtfulAccountsDiscontinuedOperations	785000
CY2010	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	-5330000
CY2011	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	822417000
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-18181000
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	5577093000
CY2011	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	9837000
CY2011	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	-694000
CY2011	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	11061000
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeTax	-6190000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	98235000
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	1154713000
CY2011	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	18424000
CY2011	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	17861000
CY2011	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	38199000
CY2011	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	95394000
CY2011	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-32712000
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	84400000
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	384000
CY2011	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	37628000
CY2011	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	12725000
CY2011	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	36249584000
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.355	pure
CY2011	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	496182000
CY2011	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	5443000
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	458014000
CY2011	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-374843000
CY2011	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	95394000
CY2011	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-10785000
CY2011	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	8.65
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	247966000
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	48718000
CY2011	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	10420066000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009	pure
CY2011	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	591313000
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.96
CY2011	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	361000
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2052000
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	48974000
CY2011	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	9687000
CY2011	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3309000
CY2011	us-gaap	Profit Loss ProfitLoss	573395000
CY2011	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax	12305000
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2033000
CY2011	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	-19328000
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	323348000
CY2011	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	6731806000
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	217886000
CY2011	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	323348000
CY2011	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1874000	shares
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	264225000
CY2011	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	75183000
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11316000
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1180046000
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1399228000
CY2011	us-gaap	Income Taxes Paid IncomeTaxesPaid	145687000
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4462000
CY2011	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	606651000
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	9721000
CY2011	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-29049000
CY2011	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	10137000
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-17918000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041	pure
CY2011	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-4756000
CY2011	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	47695000
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	400156000
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-466365000
CY2011	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	77074000
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	684715000
CY2011	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	36395105000
CY2011	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2039000
CY2011	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax	-47544000
CY2011	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	14714000
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	96532110	shares
CY2011	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	335000
CY2011	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2982000
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	88848000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	916605000
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-19987000
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.05
CY2011	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	6470540000
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-247183000
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	36000
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-986000
CY2011	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	13689000
CY2011	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	85.21
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-57000
CY2011	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.25
CY2011	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	6280306000
CY2011	us-gaap	Interest Expense Debt InterestExpenseDebt	230953000
CY2011	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	5971000
CY2011	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	3794686	shares
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	-93000
CY2011	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	4887000
CY2011	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax	-31633000
CY2011	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	100653000
CY2011	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	451500000
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	20834000
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	94658027	shares
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10270000
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	44403000
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	295099000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2011	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	-8873000
CY2011	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8776000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.003	pure
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	48718000
CY2011	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1149000
CY2011	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	420000
CY2011	us-gaap	Contributions From Noncontrolling Interests ContributionsFromNoncontrollingInterests	21010000
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	478336000
CY2011	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-659000
CY2011	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	77418000
CY2011	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-53697000
CY2011	us-gaap	Interest Paid InterestPaid	236446000
CY2011	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	18495000
CY2011	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	818662000
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	53438000
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	786000
CY2011	us-gaap	Tax Benefit From Stock Options Exercised1 TaxBenefitFromStockOptionsExercised1	38199000
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeBeforeTax	15911000
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2388000	shares
CY2011	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	-1079000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	478001000
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	20834000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.042	pure
CY2011	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	889506000
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	325292000
CY2011	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	24000000
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	478336000
CY2011	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.14
CY2011	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	553408000
CY2011	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-51979000
CY2011	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-13162000
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-602000
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21589000
CY2011	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	1077442000
CY2011	us-gaap	Discontinued Operation Provision For Loss Gain On Disposal Net Of Tax DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax	-4756000
CY2011	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	8.48
CY2011	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	127660000
CY2011	dva	Supplemental Assets Acquired Under Capital Leases SupplementalAssetsAcquiredUnderCapitalLeases	35764000
CY2011	dva	Patient Care Costs PatientCareCosts	4633620000
CY2011	dva	Debt Expense DebtExpense	241090000
CY2011	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-354000
CY2011	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	267315000
CY2011	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	340000
CY2011	dva	Proceeds From Sale Of Discontinued Operations ProceedsFromSaleOfDiscontinuedOperations	84000000
CY2011	dva	Income Tax Expense Benefit Continuing Operations And Discontinued Operations IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations	315725000
CY2011	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	467216000
CY2011	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	47051000
CY2011	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	20329000
CY2011	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	241090000
CY2011	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	496517000
CY2011	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	496517000
CY2011	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	94655000	shares
CY2011	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	3000	shares
CY2011	dva	Payments For Proceeds To Acquire Equity Method Investments And Other Assets PaymentsForProceedsToAcquireEquityMethodInvestmentsAndOtherAssets	2398000
CY2011	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-3187000
CY2011	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	190234000
CY2011	dva	Provision For Doubtful Accounts Discontinued Operations ProvisionForDoubtfulAccountsDiscontinuedOperations	4022000
CY2011	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	-5330000
CY2012	dei	Trading Symbol TradingSymbol	DVA
CY2012	dei	Entity Registrant Name EntityRegistrantName	DAVITA HEALTHCARE PARTNERS INC.
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	us-gaap	Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax	775478000
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-219000
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	6889196000
CY2012	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0516	pure
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	19029000
CY2012	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	709000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeTax	-6448000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	228698000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	1297084000
CY2012	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	16874000
CY2012	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	57241000
CY2012	us-gaap	Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions	88964000
CY2012	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	105220000
CY2012	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	7620000
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	40878000
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-983000
CY2012	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	7418000
CY2012	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-3433000
CY2012	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	39286027000
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	536236000
CY2012	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	2175000
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	540204000
CY2012	us-gaap	Targeted Or Tracking Stock Corporate Events TargetedOrTrackingStockCorporateEvents	The Company’s charter documents include provisions that may deter hostile takeovers, delay or prevent changes of control or changes in management, or limit the ability of stockholders to approve transactions that they may otherwise determine to be in their best interests. These include provisions prohibiting stockholders from acting by written consent, requiring 90 days advance notice of stockholder proposals or nominations to the Board of Directors and granting the Board of Directors the authority to issue up to five million shares of preferred stock and to determine the rights and preferences of the preferred stock without the need for further stockholder approval. The Company is also subject to Section 203 of the Delaware General Corporation Law that, subject to exceptions, would prohibit the Company from engaging in any business combinations with any interested stockholder, as defined in that section, for a period of three years following the date on which that stockholder became an interested stockholder. These restrictions may discourage, delay or prevent a change in the control of the Company
CY2012	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-32509000
CY2012	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	105220000
CY2012	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-19630000
CY2012	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	8.07
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	299810000
CY2012	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	3000000000
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	45384000
CY2012	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	10636370000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.011	pure
CY2012	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	641459000
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.47
CY2012	us-gaap	Amortization Of Leased Asset AmortizationOfLeasedAsset	103000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2102000
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	41420000
CY2012	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1664000
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4339000
CY2012	us-gaap	Profit Loss ProfitLoss	641237000
CY2012	us-gaap	Significant Supply Commitment Description SignificantSupplyCommitmentDescription	Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years.
CY2012	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax	-2498000
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1868000
CY2012	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	3926000
CY2012	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8186280000
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	263126000
CY2012	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1770000	shares
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	341969000
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.359	pure
CY2012	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	3559000
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6647000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1100848000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4832450000
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	322018000
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2345000
CY2012	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	459611000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	10130000
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
CY2012	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-6204000
CY2012	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	4250000000
CY2012	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax	-10154000
CY2012	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-5221000
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	12831000
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-222000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.040	pure
CY2012	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	Segment
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	550146000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	139996000
CY2012	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	14530000
CY2012	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	18476000
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	894575000
CY2012	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	43248175000
CY2012	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1775000
CY2012	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	26761000
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	2524000
CY2012	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y4M24D
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97971080	shares
CY2012	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3737000
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	47673000
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1205000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1001304000
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4187000
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.58
CY2012	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	7351900000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3872384000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	48000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-75000
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.58
CY2012	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Before Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesBeforeTax	6424000
CY2012	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	7116682000
CY2012	us-gaap	Interest Expense Debt InterestExpenseDebt	275723000
CY2012	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	3935000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeBeforeTax	-123000
CY2012	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	8126000
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-1205000
CY2012	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	113504000
CY2012	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	650167000
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	62036000
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96017939	shares
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4052000
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	52872000
CY2012	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	358200000
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	345066000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2012	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	-82000
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2143000
CY2012	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	16377000
CY2012	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>16.</b></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Contingencies</b></font></td> </tr> </table> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">  </p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Inquiries by the Federal Government and Certain Related Civil Proceedings</i></b></font></p> <p style="PADDING-BOTTOM: 0px; MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><u>2005 U.S. Attorney Investigation:</u> In March 2005, the Company received a subpoena from the U.S. Attorney’s Office for the Eastern District of Missouri in St. Louis. The subpoena required production of a wide range of documents relating to the Company’s operations, including documents related to, among other things, pharmaceutical and other services provided to patients, relationships with pharmaceutical companies, and financial relationships with physicians and joint ventures. The subpoena covers the period from December 1, 1996 through March 2005. In October 2005, the Company received a follow-up request for additional documents related to specific medical director and joint venture arrangements. In February 2006, the Company received an additional subpoena for documents, including certain patient records relating to the administration and billing of Epogen<font style="FONT-FAMILY: Times New Roman" size="1"><sup style="POSITION: relative; BOTTOM: 0.8ex; VERTICAL-ALIGN: baseline">®</sup></font> (EPO). In May 2007, the Company received a request for documents related to durable medical equipment and supply companies owned and operated by the Company. The Company cooperated with the inquiry and has produced the requested documents. The subpoenas were issued in connection with a joint civil and criminal investigation. It was possible that criminal proceedings could be initiated against the Company in connection with this investigation. Until recently, the Company had not received a communication from the St. Louis U.S. Attorney’s Office on this matter for nearly three years. In early October 2012, the Company announced that the government closed its investigation without filing any charges, without demanding any payments and without seeking any changes in Company policies.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><u>Woodard Private Civil Suit:</u> In February 2007, the Company received a request for information from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, for documents relating to EPO claims submitted to Medicare. In August 2007, the Company received a subpoena from the OIG seeking similar documents. The requested documents relate to services provided from 2001 to 2004 by a number of the Company’s centers. The request and subpoena were sent from the OIG’s offices in Houston and Dallas, Texas. The Company cooperated with the inquiry and has produced all previously requested documents to date. The Company was contacted by the U.S. Attorney’s Office for the Eastern District of Texas, which stated that this was a civil investigation related to EPO claims. On July 6, 2009, the U.S. District Court for the Eastern District of Texas lifted the seal on the civil <i>qui tam</i> complaint related to these previous requests for information. The Company was subsequently served with a complaint by the relator, Ivey Woodard, purportedly on behalf of the federal government, under the <i>qui tam</i> provisions of the federal False Claims Act. The government did not intervene and is not actively pursuing this matter. The relator has been pursuing the claims independently and the parties have been engaged in active litigation. The complaint contains allegations relating to the Company’s EPO practices for the period from 1992 through 2010 and seeks monetary damages and civil penalties as well as costs and expenses. The court has ruled that claims earlier than 1996 are beyond the statute of limitations. The Company believes that there is some overlap between the subject of this complaint and the review of EPO utilization in the 2005 U.S. Attorney investigation described above. The Company publicly disclosed on July 3, 2012 that it had reached an agreement in principle to settle all allegations relating to claims arising out of this matter. In connection with this settlement, the Company incurred costs and expenses of $86,000 that consists of $55,000 for the settlement plus attorney fees and related expenses. In December 2012, the settlement was finalized and the case was dismissed.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><u>Vainer Private Civil Suit:</u> In December 2008, the Company received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and EPO, as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company was in contact with the U.S. Attorney’s Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC, since November 2008 relating to this matter, and was advised that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the <i>qui tam</i> provisions of the federal False Claims Act. On April 1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney’s Office filed a notice of declination stating that the U.S. would not be intervening and not pursuing the relators’ allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to the Company’s drug administration practices for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><u>2010 U.S. Attorney Physician Relationship Investigation:</u> In May 2010, the Company received a subpoena from the OIG’s office in Dallas, Texas. The civil subpoena covers the period from January 1, 2005 to May 2010, and seeks production of a wide range of documents relating to its dialysis and related lab services, including documents related to, among other things, financial relationships with physicians and joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute and the False Claims Act. Some of the requested documents overlap with documents requested pursuant to the subpoena in the 2011 U.S. Attorney Physician Relationship Investigation described below. The Company is cooperating with the government and is producing the requested documents. However, the Company has been advised by the attorneys conducting this civil investigation that they believe that the general structure of the Company’s joint ventures does not comply with the anti-kickback statute and the False Claims Act. The Company disagrees that its joint venture structure, which the Company believes is widely used in the dialysis industry and other segments of the healthcare industry substantially in the form that the Company uses it, violates the federal anti-kickback statute or the False Claims Act. This investigation will continue to require management’s attention and significant legal expense, and the Company can make no assurances as to the final outcome.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><u>2011 U.S. Attorney Physician Relationship Investigation:</u> In August 2011, the Company announced it had learned that the U.S. Attorney’s Office for the District of Colorado would be looking into certain activities of its dialysis business in connection with information being provided to a grand jury. This investigation relates to the Company’s relationships with physicians, including its joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute, and appears to overlap, at least in part, with the 2010 U.S. Attorney Physician Relationship Investigation described above. The Company has received a number of subpoenas for documents covering the period from January 2006 to November 2012, and the Company has produced and continues to produce documents in response to those subpoenas and other requests. In addition, certain current and former members of the Board, executives and other teammates have received subpoenas to testify before the grand jury. It is possible that criminal proceedings may be initiated against the Company in connection with this investigation. This investigation will continue to require management’s attention and significant legal expense, and the Company can make no assurances as to the final outcome.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><u>2011 U.S. Attorney Medicaid Investigation:</u> In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the Office of Inspector General for the U.S. Department of Health and Human Services. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. The Company believes this inquiry is civil in nature. The Company does not know the time period or scope. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company is cooperating with the government and is producing the requested documents.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">  </p> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><u>Clark Shareholder Derivative Civil Suit</u>: As the Company previously disclosed, on August 7, 2012, a shareholder derivative lawsuit was filed in the U.S. District Court for the District of Colorado against certain current and former directors and executives of the Company and against the Company, as nominal defendant. The complaint alleges, among other things, that certain of the Company’s current and past officers and directors breached fiduciary duties to the Company relating to the previously disclosed inquiries by the federal government and <i>qui tam</i> proceedings described above. On October 12, 2012, the parties filed a joint motion to stay the case for an indefinite period as in the best interests of the Company and to conserve judicial resources. On October 19, 2012, the Court denied the stay motion but ordered that the case be administratively closed, subject to being reopened upon a showing of good cause by any party.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><u>Turner-Hooks Private Civil Suit</u>: In January 2013, the Company was served with a civil complaint filed by a former patient, Laura Turner-Hooks, and brought pursuant to the <i>qui tam</i> provisions of the federal False Claims Act purportedly on behalf of the federal government. On November 13, 2012, the U.S. District Court for the Eastern District of Michigan ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney’s Office filed a notice of declination stating that the U.S. would not be intervening and not pursuing the relator’s allegation in litigation. The relator’s complaint, originally filed in July 2011, states that she was a patient at a single dialysis facility in Michigan and that the Company allegedly violated the federal False Claims Act by providing treatments at the facility that failed to comply with the standard of care required under federal healthcare programs. The complaint asks the court to order the Company to cease committing the alleged violations and seeks monetary damages and civil penalties as well as costs and expenses. The Company intends to vigorously defend this action.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any.</font></p> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Other</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The lawsuit, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs have appealed that decision. The Company intends to continue to vigorously defend against these claims. Any potential settlement of these claims is not anticipated to be material to the Company’s consolidated financial statements.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In October 2007, the Company was contacted by the Attorney General’s Office for the State of Nevada. The Attorney General’s Office informed the Company that it was conducting a civil and criminal investigation of the Company’s operations in Nevada and that the investigation related to the billing of pharmaceuticals, including EPO. In February 2008, the Attorney General’s Office informed the Company that the civil and criminal investigation had been discontinued. The Attorney General’s Office further advised the Company that Nevada Medicaid intended to conduct audits of end stage renal disease (ESRD) dialysis providers in Nevada and such audits would relate to the issues that were the subjects of the investigation. To the Company’s knowledge, no court proceedings have been initiated against the Company at this time. Any negative audit findings could result in a substantial repayment by the Company. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.</font></p> </div>
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45384000
CY2012	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	7211000
CY2012	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-935000
CY2012	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.47
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	645424000
CY2012	us-gaap	Interest Paid InterestPaid	257640000
CY2012	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	3950000
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	800000
CY2012	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	775256000
CY2012	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	183000	shares
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	43765000
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	58369000
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-786000
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	536017000
CY2012	us-gaap	Tax Benefit From Stock Options Exercised1 TaxBenefitFromStockOptionsExercised1	88964000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeBeforeTax	16578000
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1308000	shares
CY2012	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	2401000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	536017000
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	62036000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.042	pure
CY2012	us-gaap	Health Care Organization Capitation Revenue HealthCareOrganizationCapitationRevenue	419431000
CY2012	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	4051398000
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	359845000
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><i>Use of estimates</i></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management’s best judgments at the time made. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, impairments of long-lived assets and valuation adjustments, accounting for income taxes, quarterly and annual variable compensation accruals, consolidation of variable interest entities, purchase accounting valuation estimates, other fair value estimates, stock-based compensation and medical liability claims. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.</font></p> </div>
CY2012	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	11083000
CY2012	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-222000
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1541000
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	47489000
CY2012	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	4294077000
CY2012	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	8000
CY2012	dva	Income Tax Expense Benefit Continuing Operations And Discontinued Operations IncomeTaxExpenseBenefitContinuingOperationsAndDiscontinuedOperations	359763000
CY2012	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	516387000
CY2012	dva	Goodwill Other GoodwillOther	-843000
CY2012	dva	Debt Refinancing And Redemption Charges DebtRefinancingAndRedemptionCharges	2379000
CY2012	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	52457000
CY2012	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	28011000
CY2012	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	7.91
CY2012	us-gaap	Contributions From Noncontrolling Interests ContributionsFromNoncontrollingInterests	37395000
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	536017000
CY2012	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1466000
CY2012	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-129948000
CY2012	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-51730000
CY2012	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	3904893000
CY2012	dva	Supplemental Assets Acquired Under Capital Leases SupplementalAssetsAcquiredUnderCapitalLeases	55813000
CY2012	dva	Proceeds From Issuance Of Senior Notes ProceedsFromIssuanceOfSeniorNotes	1250000000
CY2012	dva	Patient Care Costs PatientCareCosts	5578853000
CY2012	dva	Debt Expense DebtExpense	288554000
CY2012	dva	Debt Refinancing Charge DebtRefinancingCharge	10963000
CY2012	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-3384000
CY2012	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	343908000
CY2012	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	299517000
CY2012	dva	Other Operating Expenses OtherOperatingExpenses	85837000
CY2012	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	536236000
CY2012	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	536236000
CY2012	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	96198000	shares
CY2012	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	3000	shares
CY2012	dva	Common Shares Acquired For Cashless Exercise Of Warrants CommonSharesAcquiredForCashlessExerciseOfWarrants	250000	shares
CY2012	dva	Payments For Proceeds To Acquire Equity Method Investments And Other Assets PaymentsForProceedsToAcquireEquityMethodInvestmentsAndOtherAssets	2182000
CY2012	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-8214000
CY2012	dva	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Stock Appreciation And Stock Units Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsStockAppreciationAndStockUnitsWeightedAverageExercisePrice	68.74
CY2012	dva	Share Based Compensation Shares Authorized Under Stock Option Plans Stock Appreciation And Stock Units Exercise Price Range Exercisable Options Weighted Average Exercise Price ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansStockAppreciationAndStockUnitsExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice	56.85
CY2012	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	235218000
CY2012	dva	Fees And Expenses Paid FeesAndExpensesPaid	71840000
CY2012	dva	Ownership In Joint Venture OwnershipInJointVenture	0.50	pure
CY2012	dva	Health Care Partners Capitation Revenue HealthCarePartnersCapitationRevenue	419431000
CY2012	dva	Amortization Expense Benefit From Alliance And Product Supply Agreement AmortizationExpenseBenefitFromAllianceAndProductSupplyAgreement	-5330000
CY2012	dva	Segment Reporting Information Acquisitions Related Transaction Expenses SegmentReportingInformationAcquisitionsRelatedTransactionExpenses	30753000
CY2011Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	236233000
CY2011Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.96
CY2011Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-398000
CY2011Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	178479000
CY2011Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
CY2011Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1548419000
CY2011Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.98
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	94502000
CY2011Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.96
CY2011Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	270351000
CY2011Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.03
CY2011Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-13996000
CY2011Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	211010000
CY2011Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.05
CY2011Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1646612000
CY2011Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.20
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	100015000
CY2011Q2	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	24000000
CY2011Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.17
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	320882000
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.46
CY2012Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-101000
CY2012Q1	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1849533000
CY2011Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	329734000
CY2012Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	260540000
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2011Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.56
CY2011Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-19000
CY2012Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.50
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	140120000
CY2012Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.46
CY2012Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	247261000
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.99
CY2012Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	352000
CY2012Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	187392000
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.01
CY2012Q2	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1913006000
CY2012Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.01
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	95337000
CY2012Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.99
CY2011Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	318395000
CY2011Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.42
CY2011Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1251000
CY2011Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	258345000
CY2011Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.45
CY2011Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1742450000
CY2011Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.48
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	135361000
CY2011Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.45
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	340885000
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.50
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-13000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	271210000
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.52
CY2012Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1945888000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.52
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	144721000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.50
CY2011Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	268771000
CY2011Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.59
CY2011Q4	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1794325000
CY2011Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.60
CY2011Q4	us-gaap	Net Income Loss NetIncomeLoss	148123000
CY2011Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.57
CY2012Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	388056000
CY2012Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.51
CY2012Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-460000
CY2012Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	282162000
CY2012Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.54
CY2012Q4	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2477853000
CY2012Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.55
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	155839000
CY2012Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.51

Files In Submission

Name	View Source	Status
0001193125-13-085450-index-headers.html	Edgar Link	pending
0001193125-13-085450-index.html	Edgar Link	pending
0001193125-13-085450.txt	Edgar Link	pending
0001193125-13-085450-xbrl.zip	Edgar Link	pending
d465470d10k.htm	Edgar Link	pending
d465470dex1010.htm	Edgar Link	pending
d465470dex1034.htm	Edgar Link	pending
d465470dex1060.htm	Edgar Link	pending
d465470dex1061.htm	Edgar Link	pending
d465470dex1062.htm	Edgar Link	pending
d465470dex1063.htm	Edgar Link	pending
d465470dex107.htm	Edgar Link	pending
d465470dex1079.htm	Edgar Link	pending
d465470dex1089.htm	Edgar Link	pending
d465470dex121.htm	Edgar Link	pending
d465470dex211.htm	Edgar Link	pending
d465470dex231.htm	Edgar Link	pending
d465470dex311.htm	Edgar Link	pending
d465470dex312.htm	Edgar Link	pending
d465470dex321.htm	Edgar Link	pending
d465470dex322.htm	Edgar Link	pending
dva-20121231.xml	Edgar Link	completed
dva-20121231.xsd	Edgar Link	pending
dva-20121231_cal.xml	Edgar Link	unprocessable
dva-20121231_def.xml	Edgar Link	unprocessable
dva-20121231_lab.xml	Edgar Link	unprocessable
dva-20121231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2012 Form 10-K Financial Statement

#000119312513085450 Filed on March 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2012 Form 10-K Financial Statement

#000119312513085450 Filed on March 01, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva